Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Stereotactic body radiotherapy for prostate cancer.
TL;DR: SBRT has the potential to reduce costs and improve patient quality of life, but in a treatment landscape with many competing options of broadly similar efficacy, randomised trials are essential to define the relative benefits of this approach.
Journal ArticleDOI
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey Quon,Aldrich Ong,Patrick Cheung,William Chu,Hans Chung,Danny Vesprini,Amit Chowdhury,Dilip Panjwani,Geordi Pang,Renee Korol,Melanie Davidson,Ananth Ravi,Boyd McCurdy,Liying Zhang,Alexandre Mamedov,Andrea Deabreu,Andrew Loblaw +16 more
TL;DR: Prostate S BRT delivered QW improved acute bowel and urinary QOL compared to EOD and patients should be counselled regarding the potential for reduced short-term toxicity and improved QOL with QW prostate SBRT.
Journal ArticleDOI
Improved robotic stereotactic body radiation therapy plan quality and planning efficacy for organ-confined prostate cancer utilizing overlap-volume histogram-driven planning methodology
Binbin Wu,Dalong Pang,Siyuan Lei,John W. Gatti,Michael Tong,Todd McNutt,Thomas P. Kole,Anatoly Dritschilo,Sean P. Collins +8 more
TL;DR: The improvements in APs could further reduce toxicities observed in SBRT for organ-confined prostate cancer, and this study is to determine if the overlap-volume histogram (OVH)-driven planning methodology can be adapted to robotic SbrT to further minimize the bladder and rectal doses achieved in plans manually-created by clinical planners.
Journal ArticleDOI
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
H. Lukka,Stephanie L. Pugh,Deborah Watkins Bruner,Jean Paul Bahary,Colleen A. Lawton,Jason A. Efstathiou,Rajat J. Kudchadker,Lee Ponsky,Samantha A. Seaward,Ian S. Dayes,Darindra D. Gopaul,Jeff M. Michalski,Guila Delouya,Irving D. Kaplan,Eric M. Horwitz,Mack Roach,Wayne H. Pinover,David C. Beyer,John Amanie,Howard M. Sandler,Lisa A. Kachnic +20 more
TL;DR: This study confirms that, based on changes in bowel and urinary domains and toxicity (acute and late), the 5- and 12-fraction regimens are well tolerated.
Journal ArticleDOI
The Role of Hypofractionated Radiotherapy in Prostate Cancer.
TL;DR: The rationale for hypofractionation is focused on, the 5-year efficacy and toxicity outcomes from four phase III studies have been published within the last 12 months, and the evidence base for establishing moderate hyp ofractionation for localised disease as the new standard of care is presented.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more